All In Biotech

Drug Trial Radar · NCT07704658

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

A Multi-center, Open-label, Drug-drug Interaction Study to Evaluate the Effect of Pralsetinib (Gavreto) on the Pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 Substrates, and Hormones Estradiol/Norethisterone Acetate in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Mar 4, 2026

Primary completion

Jul 30, 2027

Study completion Aug 30, 2027

Sponsor

Lead sponsor
Rigel PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors

Conditions

  • NSCLC (Non-small Cell Lung Cancer)
  • Thyroid Cancer
  • Solid Tumor Malignancies
  • Advanced Malignancies

Interventions

  • PralsetinibDrug

    Pralsetinib 400mg orally (PO) once daily (QD) from Day 4 to Day 10, with an option to continue up to Day 33

  • CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptiveDrug

    Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO) once on Day 1 and once on Day 9.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf)Time frame: Up to 48 hours post-dose or as appropriate for each probe substrate
  2. Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)Time frame: Up to 48 hours after each probe drug administration
  3. Maximum Peak Plasma Concentration (Cmax)Time frame: Up to 48 hours after each probe drug administration

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain · Recruiting

  • Hospital Universitario San Pedro

    Logroño, La Rioja, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.